Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BERTRAND P COLE

Allopathic & Osteopathic Physicians Preventive Medicine Addiction Medicine

NPI
1184618852
CMS profile
53045
Location
SOMERSWORTH, NH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,439.70

62 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,356.73 58
Travel and Lodging $1,082.97 4

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BERTRAND P COLE

NPI 1184618852 · CMS profile ID 53045

Allopathic & Osteopathic Physicians / Preventive Medicine / Addiction Medicine

SOMERSWORTH, NH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BERTRAND P COLE, NPI 1184618852, CMS profile ID 53045. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). BERTRAND P COLE, NPI 1184618852, CMS profile ID 53045. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
BERTRAND P COLE, NPI 1184618852, CMS profile ID 53045, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–62 of 62 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184618852?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

62 matching records · $2,439.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 62 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–62 of 62.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $19.8701/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697835683 CMS
PFIZER INC. $101.2701/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671926133 CMS
PFIZER INC. $540.1401/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671926135 CMS
PFIZER INC. $293.2801/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671926137 CMS
PFIZER INC. $427.9301/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671926139 CMS
PFIZER INC. $7.7701/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671866059 CMS
PFIZER INC. $2.8301/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671866293 CMS
Pernix Therapeutics Holdings, Inc. $13.9701/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703311481 CMS
Lilly USA, LLC $14.6401/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657718803 CMS
Shionogi Inc $12.9201/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688777773 CMS
PFIZER INC. $3.0701/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671866017 CMS
PFIZER INC. $13.2401/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671891805 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,439.70 62
PY2020 $193.41 11
PY2023 $74.23 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $870,228.90 54
PY2024 Principal investigator $1,905,180.28 179
PY2023 Principal investigator $1,443,179.04 289
PY2022 Principal investigator $251,564.05 26
PY2021 Principal investigator $127,528.47 7
PY2020 Principal investigator $6,130.68 3
PY2019 Principal investigator $167,873.49 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,187.90 12/16/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228738060
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,800.00 11/26/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185546003
Principal investigator 1 GlaxoSmithKline, LLC. $398.00 11/25/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157624
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,800.00 11/14/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185546001
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,310.00 11/12/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185546009
Principal investigator 1 ModernaTX, Inc. $800.00 11/10/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956553
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/23/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956559
Principal investigator 1 ModernaTX, Inc. $1,950.00 10/23/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956561
Principal investigator 1 ModernaTX, Inc. $2,100.00 10/23/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956563
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/23/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956565
Principal investigator 1 ModernaTX, Inc. $2,142.00 10/17/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956557
Principal investigator 1 GlaxoSmithKline, LLC. $3,883.86 10/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157628
Principal investigator 1 GlaxoSmithKline, LLC. $849.66 09/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157634
Principal investigator 1 PFIZER INC. $4,700.00 08/22/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228787909
Principal investigator 1 GlaxoSmithKline, LLC. $4,212.04 08/13/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192155197
Principal investigator 1 GlaxoSmithKline, LLC. $686.00 08/06/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192155193
Principal investigator 1 PFIZER INC. $450.00 08/06/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228767530
Principal investigator 1 GlaxoSmithKline, LLC. $49.00 07/23/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157631
Principal investigator 1 PFIZER INC. $596.95 07/11/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228789609
Principal investigator 1 PFIZER INC. $46,281.55 06/27/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228777775
Principal investigator 1 PFIZER INC. $2,927.40 06/26/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228775811
Principal investigator 1 PFIZER INC. $43,277.85 06/21/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228777200
Principal investigator 1 PFIZER INC. $54,265.63 06/21/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228790466
Principal investigator 1 PFIZER INC. $65,833.25 06/14/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723466
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,117.96 06/06/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185546013
Principal investigator 1 PFIZER INC. $36,402.38 06/06/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228775800
Principal investigator 1 ModernaTX, Inc. $1,690.00 06/04/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956567
Principal investigator 1 PFIZER INC. $7,740.00 06/04/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228793252
Principal investigator 1 Currax Pharmaceuticals LLC $554.18 05/28/2025 Non-covered Recipient Entity
Activmed Practices And Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715350
Principal investigator 1 GlaxoSmithKline, LLC. $610.54 05/21/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157616
Principal investigator 1 PFIZER INC. $123,904.62 04/29/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228798161
Principal investigator 1 PFIZER INC. $13,902.10 04/25/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228781059
Principal investigator 1 Currax Pharmaceuticals LLC $452.93 04/24/2025 Non-covered Recipient Entity
Activmed Practices And Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715348
Principal investigator 1 GlaxoSmithKline, LLC. $1,763.02 04/23/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157620
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,952.46 04/17/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185546007
Principal investigator 1 PFIZER INC. $60,241.16 04/10/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228723186
Principal investigator 1 GlaxoSmithKline, LLC. $4,047.40 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192157611
Principal investigator 1 PFIZER INC. $264.20 04/01/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228719541
Principal investigator 1 PFIZER INC. $2,103.64 04/01/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228796018
Principal investigator 1 AstraZeneca Pharmaceuticals LP $190,369.79 03/28/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity No dispute reported 06/30/2026 1185546015
Principal investigator 1 Currax Pharmaceuticals LLC $1,088.11 03/27/2025 Non-covered Recipient Entity
Activmed Practices And Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715340
Principal investigator 1 PFIZER INC. $10,300.00 03/12/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228779876
Principal investigator 1 ModernaTX, Inc. $1,803.39 02/27/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age No dispute reported 06/30/2026 1252956555
Principal investigator 1 GlaxoSmithKline, LLC. $4,140.50 02/25/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192155201
Principal investigator 1 Currax Pharmaceuticals LLC $5,163.68 02/20/2025 Non-covered Recipient Entity
Activmed Practices And Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715336
Principal investigator 1 GlaxoSmithKline, LLC. $14,589.26 02/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192155206
Principal investigator 1 Currax Pharmaceuticals LLC $2,216.72 01/30/2025 Non-covered Recipient Entity
Activmed Practices And Research LLC
NB (Contrave) Cardiovascular Outcomes Trial No dispute reported 06/30/2026 1242715334
Principal investigator 1 PFIZER INC. $3,186.56 01/29/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228799808
Principal investigator 1 SANOFI PASTEUR INC. $24,800.00 01/28/2025 Non-covered Recipient Entity
Activmed Practices And Research Llc
A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226089042
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,084.00 01/15/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185546005
Principal investigator 1 PFIZER INC. $6,456.45 01/09/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228801233
Principal investigator 1 PFIZER INC. $812.28 01/08/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228800202
Principal investigator 1 AstraZeneca UK Limited $27,159.96 01/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185546011
Principal investigator 1 PFIZER INC. $7,310.52 01/01/2025 Non-covered Recipient Entity
ActivMed Practices Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228802030